Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K9 | P80192 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | CASP3 | P42574 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 2/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8857148 | 0.85 | PNMT (0.43) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL29859431 | 0.85 | PNMT (0.43) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL9841135 | 0.80 | PGR (0.40) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL27335605 | 0.79 | PNMT (0.44) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| Hydrochloric Acid SCHEMBL5347494 | 0.79 | MAP3K9 (0.40) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL13777275 | 0.79 | PNMT (0.39) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL7873617 | 0.79 | PNMT (0.39) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL7141052 | 0.79 | PNMT (0.39) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| SCHEMBL5404545 | 0.79 | PNMT (0.42) | MAP3K9MAP3K11MAOAPNMTNPC1 | |
| Hydrochloric Acid SCHEMBL9579948 | 0.79 | MAP3K9 (0.41) | MAP3K9MAP3K11MAOAPNMTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169816-B2 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7019033-B2 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | WARNER-LAMBERT COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | WARNER-LAMBERT COMPANY LLC | 2006-03-09 | — | — | US | disclosed |
| US-6972298-B2 | Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor | WARNER-LAMBERT COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1140291-B1 | COMBINATION CHEMOTHERAPY COMPRISING A MITOTIC INHIBITOR AND A MEK INHIBITOR | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1140062-B1 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER LAMBERT CO (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BARRETT STEPHEN DOUGLAS (US) | 2005-03-03 | — | — | US | disclosed |
| US-6821963-B2 | PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES INHIBIT CERTAIN DUAL SPECIFICITY KINASE ENZYMES INVOLVED IN PROLIFERATIVE DISEASES SUCH AS CANCER, PSORIASIS AND RESTENOSIS; INHIBIT THE PHOSPHORYLATION OF MAP KINASE BY MEK | WARNER-LAMBERT COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-0993439-B1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0993437-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001421-A1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052608-A1 | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | MAP3K9 22/4885MAP3K11 7/4885MAOA 1112/4885 |
| US-20050049429-A1 | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors | BRAF, MAPK1, MAPK4 | MAP3K9 22/4885MAP3K11 7/4885MAOA 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.